Latest From GlycoMimetics Inc.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.
- Drug Discovery Tools
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- GlycoMimetics Inc.
- Senior Management
Rachel K King, CEO
Brian Hahn, SVP, CFO
John Magnani, PhD, SVP, Research & CSO
Armand Girard, SVP, Strategy & Corp. Dev.
Eric Feldman, MD, VP, Clinical Dev.
- Contact Info
Phone: (240) 243-1201
9708 Medical Center Dr.
Rockville, MD 20850
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.